The firm will combine every 15 shares into one share in order to comply with Nasdaq's minimum bid price requirement.

A 51-year-old man with limb-girdle muscular dystrophy died after receiving Sarepta's experimental gene therapy and experiencing acute liver failure.

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

For $1.8 million upfront and additional contingent and milestone payments, I-Mab gains full rights to givastomig's parental antibody.

In a final draft guidance, the committee recommended the treatment for HR-positive HER2-negative early breast cancer patients, regardless of lymph node involvement.

The privately funded basket trial makes good on its aim to enroll underrepresented groups amid a DEI-hostile federal funding ...

The company will pause several gene therapy development programs, for which it intends to seek partners and other strategic alternatives.

The participating regions are home to 84 percent of sickle cell Medicaid patients who could gain access to gene therapies under outcomes-based agreements.

A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

The company hopes to commercialize its tumor profiling assay after it secures $10 million via a share purchase agreement.

The revenue for the cell therapy Carvykti and the EGFR-targeted lung cancer duo Rybrevant-Lazcluze contributed to double digit gains in oncology drug sales.